GlassScriptPhysician profile
Fadi Alali
NPI 1104073022
$1,619.85
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $376 · 2021: $541 · 2022: $261.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $333.31 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $221.00 | 2019-2022 | |
| Gilead Sciences, INC. | $216.42 | 2020-2022 | |
| Janssen Biotech, INC. | $212.62 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $134.44 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.17 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $114.96 | 2021 | |
| Cook Medical LLC | $109.72 | 2020-2022 | |
| Ambu INC. | $97.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.04 | 2021 | |
| Ironwood Pharmaceuticals, INC | $19.83 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Alali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.